Nomination committee in IRLAB appointed ahead of annual general meeting 2021
IRLAB (Nasdaq Stockholm: IRLAB A) announced today that in preparation for the annual general meeting 2021, the company’s three largest shareholders, or groups of shareholders, have appointed members of the nomination committee. The nomination committee consists of Daniel Johnsson, Bo Rydlinger and Clas Sonesson beside Gunnar Olsson, the chairman of the board. The nomination committee represents about 53 percent of shares and votes in the company.
According to the instruction for appointment of the nomination committee in IRLAB Therapeutics AB, resolved at the annual general meeting on May 7, 2020, the nomination committee shall, besides the chairman of the board, consist of representatives of the three largest shareholders, or groups of shareholders, as per August 31.
As the three largest shareholders or groups of shareholders now have appointed their representatives, the nomination committee has held its first meeting. The nomination committee consists of the following members:
- Daniel Johnsson, chairman of the nomination committee, entrepreneur, business developer and investor, appointed by a group of shareholders representing about 23 percent of shares and votes;
- Bo Rydlinger, background from banking and investments, appointed by a group of shareholders representing about 19 percent of shares and votes;
- Clas Sonesson, Chief Scientific Officer (CSO) at IRLAB and one of IRLAB’s founders. Appointed by a group of shareholders that consists of the company’s founders representing about 11 percent of shares and votes; and
- Gunnar Olsson, chairman of the board of IRLAB Therapeutics AB.
Information about the nomination committee’s work and the instruction to the nomination committee can be found on the company website under the section for Corporate Governance. The nomination committee’s proposal will be presented in the summon to the annual general meeting 2021 and on the company’s web page: www.irlab.se.
Shareholders who wish to submit proposals to the nomination committee may contact the nomination committee at the company’s postal address or e-mail: firstname.lastname@example.org. In order to enable the nomination committee to take proposals into consideration, they must be submitted in reasonable time prior to the annual general meeting and no later than January 31, 2021.
For more information
Daniel Johnsson, chairman of the nomination committee
Phone: +46 736 87 64 00
Gunnar Olsson, chairman of the board
Phone: +46 705 76 14 02
IRLAB is a Swedish research and development company that focuses on developing novel treatments in Parkinson’s disease. The company's most advanced candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which completed Phase IIa-studies, intends to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through the proprietary research platform, ISP (The Integrative Screening Process), IRLAB discovers and develops unique drug candidates for central nervous system (CNS) related disorders where large and growing medical need exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. IRLAB is listed on Nasdaq Stockholm Main Market. More information on www.irlab.se.